(Adnkronos) - Nella Giornata mondiale per il cuore, flash mob a Roma per campagna "Liberiamo la circolazione dal colesterolo"
Sirm presenta R7 - Radiology, il *Forum internazionale di radiologia
Prevenzione, innovazione, sostenibilità al centro dell’evento per i 75 anni di Abbott
I ragazzi della Naba di Milano presentano “Luce tra i frammenti”, un cortometraggio che apre nuova narrazione sui tumori ematologici
Con Sma Talent School le persone con atrofia muscolare spinale ritrovano la propria voce
Happy Ageing, a Roma la terza edizione degli Stati generali dell’invecchiamento attivo
Presentato il position paper “Tumore al Polmone: la Via Maestra è la Diagnosi Precoce”
Leucemia linfoblastica acuta, blinatumomab aumenta significativamente sopravvivenza in pazienti di nuova diagnosi
Da Menarini nuove prospettive terapeutiche per tumori del sangue
Cancro del polmone ancora 'big killer', nel Lazio 3.500 casi all'anno –
A seguire la 4° puntata della Serie “Tumore al seno e rientro al lavoro” dal titolo: Il percorso psicologico dalla diagnosi al rientro al lavoro
Sirm presenta R7 - Radiology, il *Forum internazionale di radiologia
Prevenzione, innovazione, sostenibilità al centro dell’evento per i 75 anni di Abbott
I ragazzi della Naba di Milano presentano “Luce tra i frammenti”, un cortometraggio che apre nuova narrazione sui tumori ematologici
Con Sma Talent School le persone con atrofia muscolare spinale ritrovano la propria voce
Happy Ageing, a Roma la terza edizione degli Stati generali dell’invecchiamento attivo
Presentato il position paper “Tumore al Polmone: la Via Maestra è la Diagnosi Precoce”
Leucemia linfoblastica acuta, blinatumomab aumenta significativamente sopravvivenza in pazienti di nuova diagnosi
Da Menarini nuove prospettive terapeutiche per tumori del sangue
Cancro del polmone ancora 'big killer', nel Lazio 3.500 casi all'anno –
A seguire la 4° puntata della Serie “Tumore al seno e rientro al lavoro” dal titolo: Il percorso psicologico dalla diagnosi al rientro al lavoro
Category
🗞
NewsTranscript
00:00In this issue, in the World Day for the Heart, Flashmob Rome, in the countryside, we free
00:16the circulation from cholesterol.
00:18SIRM presents R7 Radiology, the international forum of radiology.
00:24Prevention, innovation and sustainability at the center of the event for the 75 years
00:29of Abbott.
00:30The boys of the NAB of Milan present Light between the Fragments, a short film that opens
00:36a new narrative on hematological tumors.
00:39With Smart Talent School, people with muscle atrophy and spinal, find their voice.
00:45And again, Happy Aging, in Rome, the third edition of the General States of Active Aging.
00:52Presented the Position Paper, lung tumors, the master way is the early diagnosis.
00:58Acute lymphoblastic leukemia, Blimatumobab, significantly increases survival in patients
01:05of new diagnosis.
01:06From Menarini, new therapeutic prospects for blood tumors.
01:10Lung cancer, still a big killer, in Lazio, 3,500 cases a year.
01:17To follow the fourth episode of the series, Tumor to the Breast and Back to Work, from the title
01:22the psychological path, from diagnosis to return to work.
01:32In the World Heart Day, which is celebrated on September 29, the Flashmob organized in
01:37Rome for the campaign, we free the circulation from cholesterol, has achieved great success
01:42attracting the attention and participation of hundreds of citizens.
01:46The initiative, promoted by Deici San Chietale, with the sponsorship of important health associations
01:51like Alice Lazio, has offered free screenings for the population, raising awareness
01:55on the importance of the prevention of cardiovascular diseases.
01:59Professor Marcello Arca, Director of the Department of Internal Medicine and Diseases
02:03Metabolic of the Policlinic Umberto I of Rome, has emphasized the importance of prevention.
02:08All studies have clearly shown that high levels of cholesterol are the main
02:14cause of atherosclerosis and heart attack, and therefore it must be cured.
02:20Hypercholesterolemia must first be researched and then cured.
02:24I say research because the vast majority of people who have high
02:29levels of cholesterol, before the heart attack, are doing very well.
02:34They do not show symptoms, they are in excellent condition and therefore hardly think
02:39of laboratory clinical tests to find out if they have high levels of cholesterol.
02:45And so it is important that there is more awareness of regular tests,
02:52which can be asked of family doctors, or they can also be inserted, as they say,
02:57in opportunistic tests, which are dedicated to studying other conditions,
03:03but in the tests you can also insert measurements of cholesterol.
03:08Why is this? Because we have excellent tools to cure hypercholesterolemia,
03:14which can range from interventions on lifestyle, in particular on eating habits,
03:20but also interventions that take the use of drugs, which have been in use for many years,
03:28are safe, in the vast majority of cases, and are effective,
03:34as they are able to determine the reduction of the levels of cholesterol,
03:39which is suitable for their cardiovascular risk.
03:42And the big advantage is that the choice of drug can be drawn and cut out
03:48on the characteristics of each individual.
03:51So, to use a slogan, we can say that we have the right drugs for almost all patients.
03:57President Alice Lazio and Fabrizio Fennacchi have reiterated the crucial role of prevention
04:02in the fight against cardiovascular diseases.
04:05Prevention is the most important tool to prevent the disease from causing unsustainable damage,
04:14both for the community and for the families.
04:18Prevention is carried out through screening interventions,
04:22simple check-ups, carried out with professional doctors,
04:27who, even with the help of non-invasive instruments,
04:31can tell us what the state of our blood pressure is,
04:37of the sugar in our blood, or even the state of cholesterol and dyslipidemia.
04:43Another thing that helps in terms of prevention is the adoption of healthier lifestyle habits,
04:52which are more in line with the objectives of avoiding having a heart or cerebrovascular disease.
05:03So, exercise, eat properly,
05:08reduce or reduce the consumption of alcohol and smoke.
05:13In essence, prevention is getting informed, taking care of yourself
05:19and doing what is best for your health.
05:23With this flashmob, Dai Ichisankyo has shown that an innovative approach
05:27can raise awareness among the public about the risks of high cholesterol.
05:31So, on World Heart Day, we are delighted, Dai Ichisankyo,
05:36to be here to support this event.
05:39We decided to do something a little innovative, a little fun,
05:43using cholesterol balls to try to show people
05:46the importance and what happens in the body when you have high cholesterol.
05:50Cardiovascular diseases are still one of the main causes of death in Europe,
05:54and cardiovascular diseases, in particular hyperlipidemia, are silent killers.
06:00So, it is really important that patients are aware of this,
06:04that they get tested and follow the treatment.
06:06As a doctor, I understand how difficult it can be
06:10and how complicated it is to convince patients to do so.
06:13We have collaborated with associations, with patients' associations,
06:17and we are delighted to be here at this event.
06:20It is really important for us to see that we are not just an innovative pharmaceutical company
06:25at a global level, but we are a global health care company
06:27that contributes to the well-being of society.
06:29The event has shown how greater awareness and prevention
06:33can make a difference in the fight against cardiovascular diseases,
06:37the leading cause of mortality in Italy.
06:44The International Forum
06:47An international forum that, for the first time,
06:49involves the radiology companies of the G7 countries
06:52in order to promote prevention and improve care in a sustainable health.
06:57It is R7 Radiology,
06:59the meeting promoted by the Italian Society of Interventional Medical Radiology,
07:04which will take place in Venice from October 10 to 13,
07:07and which will be attended by the presidents of the radiology companies
07:11of the United States, the United Kingdom, Germany, France, Japan, Canada, Italy
07:15and the European Society of Radiology.
07:18It is the first time that the seven radiological leaders of the world
07:22come together to discuss the great issues of the discipline,
07:27the great issues of the health of the future,
07:29the fragile patient, sustainability, artificial intelligence and precision medicine,
07:36and to move on to two very important and delicate issues,
07:40that is, the burnout of the operators
07:46and therefore the working conditions within a radiology
07:49that is increasingly the central part of the process
07:52and of the diagnostic and therapeutic work-up of the patients,
07:55and finally, the modalities and the problems
07:59that the new generation of radiologists,
08:01the transfer of knowledge,
08:03therefore of education to the new generation of radiologists,
08:07imposes on this society and this science
08:10and this really important novelty of the new technologies
08:16that are imposing on our discipline.
08:18The meeting will be for the experts a precious opportunity to exchange and compare
08:22on the main issues that concern the present and the future of the discipline.
08:26As always, the comparison can only bring mental openness, benefits.
08:31Why? Because we compare not only the technological advances,
08:36but also different ways of managing health,
08:41the organizational aspects, the health systems in comparison.
08:44Therefore, it is important to share also possible strategic choices
08:51to make the system and to bring what is good in every nation of the organization.
08:58This concerns the use of technologies and technological advances,
09:03the use and the future of radiology, telemedicine and artificial intelligence,
09:09which are the hottest issues today
09:12and will certainly be our next organizational issues.
09:22The Health to the Fullest meeting was held in Rome,
09:26next to the Patients for Prevention, Innovation and Sustainability,
09:30promoted by Abbott on the occasion of its 75th anniversary.
09:34The focus was on the challenges of the national health system.
09:38Among the innovations, there are those in interventional cardiology
09:41to deal with cardiovascular diseases
09:44that, with 217,000 deaths a year, represent the first cause of death in Italy.
09:49Cardiology in general and interventional cardiology in particular
09:53have made huge strides from all points of view, diagnostic and therapeutic.
09:58But in recent years, there has been a remarkable evolution
10:04in the field of interventional cardiology,
10:07as several methods that have been progressively introduced,
10:13such as advanced diagnostic methods, endovascular imaging
10:18or study of the physiology of coronary vessels,
10:21have become more and more common
10:24and have been tested in various clinical studies
10:27and have proven to be able to help us
10:31to make our interventions and procedures better and better,
10:35thus improving the outcome for patients.
10:39In Italy, the emergency related to diabetes remains high,
10:42which affects about 4 million citizens.
10:45A disease that is increasingly addressed thanks to technology.
10:48Of course, technology, in all its forms,
10:51is a great help to ensure that the person with diabetes
10:55lives a life as equal as possible to that of people without diabetes.
11:00Among these, we also include, for example,
11:02the most modern continuous monitoring systems of the IMCA,
11:07but we also include all those possibilities
11:10of the formation of telematic networks
11:13that connect the person with diabetes
11:16and the operators around it,
11:19so that the assistance is as integrated as possible.
11:23In the oncological field,
11:25situations such as involuntary weight loss
11:28and muscle tone, lack of appetite,
11:31and irregularity of the intestinal function should not be underestimated.
11:33Preventing weight loss and muscle loss,
11:37which means loss of function,
11:39loss of ability to perform normal daily functions,
11:42is possible,
11:44provided that the awareness of the problem
11:47increases within the medical class
11:50and the healthcare workers
11:52who take care of the oncological patient.
11:56The early interception of the mechanisms
12:00that interfere with normal diet
12:04and therefore determine weight loss is fundamental.
12:07Therefore, it is important that the oncological patient
12:10is taken care of from a metabolic and nutritional point of view
12:15from the beginning of his illness,
12:18that is, from the moment of diagnosis.
12:20For some people at that moment there will be nothing to do,
12:23for others, on the other hand, it may be necessary
12:26to start a nutritional therapy
12:29that can allow the patient
12:32to face the therapeutic path in an optimal way.
12:38Represent and give voice to people affected by hematological tumor
12:44so that public opinion can understand the fears and fears
12:48with which they have to live every day,
12:50but also trust in research and therapies.
12:53A message of hope, therefore,
12:55the one launched by light among the fragments,
12:58the journey of Mira, from the discovery of the disease
13:01to hope with CAR-T,
13:03a 2D animated short film
13:05produced by the students of the Triennium in Cinema and Animation of NABA,
13:09New Academy of Fine Arts of Milan
13:12and promoted by Gilead Sciences
13:14with the sponsorship of AILE,
13:16the Italian Association Against Leukemia, Lymphoma and Myeloma
13:20and the Lampad of Aladino ETS.
13:22Innovation changes the history of diseases in blood tumors
13:25and today we finally talk about concrete hopes.
13:28Innovation is describing how these diseases are changing.
13:31Today we are here to talk about a short film
13:34that had the great initial bet
13:37to describe in a simple way
13:39a very complex thing.
13:41We are not talking about drugs, we are talking about a process,
13:43CAR-T is a process
13:45and the great bet was to make them understandable to anyone.
13:49The guys at NABA were splendid,
13:51they managed to make a fantastic product
13:53and from tomorrow we will obviously distribute it to everyone
13:56because in the end the things that are known are less scary
13:59and the patients need it.
14:01The short film tells the possibility of a cure
14:04through a new innovative therapy,
14:06CAR-T,
14:07which represents the moment when hope is rekindled.
14:11It is more than a hope for some of them,
14:13it is a reality today,
14:15the possibility of being healed
14:17despite the refractoryness to a standard therapy.
14:21So it is a journey,
14:23certainly there is a complex therapy,
14:25it is a long process,
14:27but it can really, in some indications,
14:29such as in the infamous B-cell diffuse,
14:32which does not respond to a line of traditional chemotherapy,
14:36restore in 50% of cases a cure.
14:39Many patients can access this innovative therapy.
14:43There could be more than what we can really cure today,
14:49but the important thing is to identify them in time
14:54so that they can know what this therapeutic alternative is
15:00and face it in the best way.
15:02Among the objectives of the short film,
15:04also the sensitization.
15:06Both at the community level,
15:08to be close to the patients in their path of healing
15:13and hopefully healing,
15:15but the goal of sensitization
15:19is also to make patients aware
15:22of the scenarios and the possibilities of treatment,
15:26therefore also increase their possibilities of healing.
15:34People with SMA can now find and make their voice heard
15:38with SMA Talent School,
15:40an online training project of nine months,
15:43to discover and enhance vocal skills
15:46for those who live with SMA, spinal muscular atrophy.
15:49Didactic partner of the initiative,
15:51the School of High Professional Training,
15:53Academy 09 of Milan.
15:55The project is developed by the NEMO Clinical Centers,
15:58the National Network of Experts Centers for Cure and Research
16:01on Neuromuscular Pathologies
16:03and by the SMA family,
16:04the National Association of References for this Pathology,
16:07together with Roche.
16:08We were able to create this project,
16:10which inserts professionalism
16:13on those who are objectives of desire
16:17of people, from singing to acting,
16:20and so we have further expanded
16:22this type of relationship capacity,
16:25our clinics will be available,
16:28I think we have broken the fourth wall,
16:31as they say, in the theater
16:33and we have come to tell ourselves even more outside
16:37and to be able to tell people with SMA,
16:40you decide who you are, what you want to do
16:43and do it using your voice strongly.
16:47Through SMA Talent School,
16:49the voice of people has no boundaries
16:51and becomes a resonance box for a culture of inclusion
16:54centered on the value of the person.
16:56In this project, people with SMA have the opportunity
16:59to implement their light,
17:03to work on their ability to communicate,
17:06but also to communicate to the world
17:08that having SMA does not just mean
17:10being on a wheelchair,
17:12but it also means that through wheelchairs
17:14we can move and we can go into the world
17:17with people to tell through our voice,
17:20our life, what we are and what we do.
17:23The academic path involves 67 participants
17:27between the ages of 9 and 63,
17:30a project that wants to raise awareness
17:32on spinal muscular atrophy,
17:34which in Italy affects every year
17:36a child over 10,000
17:37and leads to the progressive loss
17:39of motor skills.
17:41This project was born from a collaboration
17:43with the SMA family and the Cinemo clinical centers.
17:46We could not not embrace it,
17:48believing deeply in the possibility
17:51of creating together a more inclusive society.
17:59Aging in health and prevention through vaccination
18:02are the themes at the longevity center
18:04Conquista, Risk and Opportunity,
18:06the third edition of the General States
18:08of Active Aging,
18:09organized in Rome by Happy Aging,
18:11the Italian Alliance for Active Aging.
18:13The Italian population is in fact
18:15ever longer, a health achievement
18:17of a health system that has been able
18:19to guarantee prevention and care
18:21and to which risk and opportunity are linked.
18:24To endanger the health of the frail
18:26and the elderly, as well as children,
18:28and preventable thanks to the vaccine,
18:30are respiratory infections
18:32such as influenza, covid, pneumococcus.
18:35At the moment, the National Vaccine Prevention Plan
18:382023-2025 is in force.
18:41The offers are the anti-influenza vaccine,
18:45the anti-pneumococcus vaccine,
18:47the anti-zoster vaccine and the covid call.
18:50Of course, these vaccines for the interested categories
18:54which are for the most part the elderly
18:57and the frail subjects.
18:59Particularly risky for the elderly
19:01is the syncytial respiratory virus.
19:03It is a very dangerous virus
19:05because it gives bronchiolitis and bronchitis,
19:07very important respiratory pathologies
19:09which often lead to resuscitation
19:12or even many deaths
19:14linked to this pathology.
19:16It is a virus that we encounter now,
19:18after covid,
19:20when there are lung diseases,
19:22now the diagnosis is done
19:24with instruments that are now
19:26certainly increased,
19:28so we can count how many diseases
19:30there are from the syncytial respiratory virus
19:32and we know that we can avoid it
19:34with vaccination.
19:36But the vaccine against the syncytial respiratory virus,
19:38being recently approved,
19:40has not yet been included
19:42in the National Vaccine Prevention Plan.
19:44This worries us because the winter season
19:46is about to arrive and therefore
19:48the virus does not meet the regional laws
19:50or the implementation of the plan.
19:52We could have the fact that in some regions
19:54the elderly could be protected,
19:56in some other regions not.
19:57The regions that can economically support
19:59the offer of this new prevention tool
20:01to their own population
20:03are being activated,
20:05but the risk of disparities in access
20:07to prevention and health
20:09worries experts.
20:11The hope is that there is
20:13an equity of supply of vaccinations,
20:15because we risk
20:17to have,
20:19and in part it is already happening,
20:21the regions that are more
20:23sensitive to the issue,
20:25with more technical resources,
20:27with perhaps more economic resources,
20:29that are going to make innovative
20:31proposals and other regions
20:33that are left behind.
20:35The 2017 calendar
20:37had that great merit
20:39of bringing back
20:41the equity of supply,
20:43that is, the elderly,
20:45as children, as teenagers,
20:47in all Italian regions,
20:49must have the same
20:51possibilities of preventing diseases.
20:53In 2023,
20:55in Italy,
20:57about 44,000 new
20:59lung cancer diagnoses
21:01were registered,
21:03which is attested
21:05among the most frequent neoplasies,
21:07particularly among men.
21:09The deaths in 2022
21:11were 35,700,
21:13numbers that tell what
21:15in our country has now become
21:17a significant health
21:19and social challenge.
21:21In Rome, at the press room
21:23of the House of Representatives,
21:25at the institutional event
21:27of the presentation of the position paper
21:29Lung Tumors, the Master Way
21:31and the Early Diagnosis,
21:33made with the non-conditioned contribution
21:35of Johnson & Johnson MedTech,
21:37a document that underlines
21:39the importance and need
21:41to promote screening programs
21:43for lung tumors
21:45intended for the target population.
21:47The goal is to increase
21:49the national health system
21:51dedicated to all screenings
21:53and in particular
21:55to promote the censorship
21:57of the population at risk,
21:59therefore smokers and genetically predisposed,
22:01because
22:03even familiarity
22:05today represents
22:07one of the multifactorial stimuli
22:09that can affect
22:11lung neoplasia.
22:1345% of patients who
22:15have lung tumor diagnosis
22:17already have a locally advanced disease.
22:19We must identify patients
22:21who are currently healthy
22:23but who have high risk factors
22:25and on those our efforts converge.
22:27And do what?
22:29The thing to do is to do
22:31a high-resolution thoracic attack
22:33and low dosage,
22:35so little radiation for the patient
22:37but many results in image quality
22:39and therefore with these images we can
22:41above all find lungs in the initial phase
22:43and also find associated pathologies,
22:45lung pathologies,
22:47so it is an important work.
22:49The master way is therefore
22:51the early diagnosis,
22:53also for the benefit of the national health system.
22:55It is absolutely necessary
22:57to identify people
22:59so-called healthy subjects
23:01at risk.
23:03Who are the healthy subjects at risk?
23:05They are smokers
23:07who reach the age of 50
23:09and it is as if they were crossing a door
23:11and this door is
23:13the subject at risk.
23:15At the risk of what?
23:17Of developing a primitive neoplasia
23:19of the lung,
23:21of having very serious damage
23:23to the coronary arteries,
23:25of having serious damage
23:27at the parenchymal level
23:29and therefore become bronchitis,
23:31chronic and emphysema.
23:33So with these screening programs
23:35it is possible to identify
23:37these three pathologies
23:39that are very important
23:41for the public species.
23:47There are about 450 Italian adults
23:49affected by acute lymphoblastic leukemia every year,
23:51a tumor of rapid blood progression
23:53with high mortality.
23:55Research and development of new therapies
23:57are making great strides,
23:59as shown by the data of the clinical study
24:01of phases 3 and 19-10,
24:03recently published in the New England Journal of Medicine.
24:05The study shows
24:07that in patients affected by acute lymphoblastic leukemia
24:09with negative philadelphia
24:11and no trace of detectable disease,
24:13after the initial treatment,
24:15the addition of the B-specific antibody
24:17Blinatumumab to chemotherapy
24:19significantly increases
24:21survival.
24:23The study that was recently published
24:25in the New England Journal of Medicine
24:27is an extremely important study
24:29because it shows in a randomized study
24:31therefore with a group of comparison
24:33that the addition of the
24:35B-specific monoclonal antibody
24:37Blinatumumab, which is a form of immunotherapy
24:39is also active
24:41in patients who are
24:43with acute lymphoblastic leukemia,
24:45negative philadelphia of the B-line,
24:47which are negative
24:49also for the minimal disease.
24:51So it is an extremely important step forward
24:53for the treatment of these patients
24:55in the front line.
24:57The scope of the change
24:59immunotherapy has given way to
25:01is allowing the clinic to look at a new goal
25:03in the adult population, that of healing.
25:05The goal today
25:07is healing
25:09and it is formidable
25:11to be able to affirm this
25:13also in adult patients.
25:15Today we employ
25:17in research protocols
25:19patients up to 65 years
25:21and beyond, with the goal
25:23to bring them to healing.
25:25Blinatumumab is the first immunotherapy
25:27developed with the BITE platform
25:29B-specific T-cell Engager
25:31by Amgen.
25:33This platform has had
25:35an extremely innovative approach
25:37based on the
25:39innovative connection between
25:41biology and technology.
25:43It started, of course,
25:45from acute lymphoblastic
25:47leukemia
25:49in the recidivism phase,
25:51and then advanced
25:53towards earlier stages
25:55of the disease, going through
25:57the so-called minimal residue disease,
25:59that is, leukemic clones present
26:01a minimal residue, but which inevitably
26:03lead to clinical and
26:05hematological relapse
26:07of the patient, up to
26:09first-line development.
26:15The Italian Pharmaceutical Agency
26:17has approved the reimbursement of
26:19Selinexor for the treatment of
26:21adult patients with multiple myeloma
26:23subjected to at least a previous therapy.
26:25The selective oral inhibitor
26:27of the XPO1 protein is therefore
26:29reimbursable in two ways.
26:31The first is for
26:33the use of
26:35Selinexor
26:37in association
26:39with desamethasone,
26:41which is a cortisone,
26:43as a fifth-line
26:45therapy
26:47in patients who have
26:49previously been exposed
26:51to two
26:53proteasome inhibitors,
26:55to two immunomodulators
26:57and to a monoclonal
26:59anti-CD38 antibody.
27:01The other indication,
27:03instead, is in association
27:05with an inhibitor
27:07of the proteasome.
27:09It is called Bortezomib.
27:11Selinexor and Bortezomib
27:13in association
27:15with desamethasone
27:17have received approval
27:19on the basis of the results
27:21of a Phase III study,
27:23the Boston study.
27:25The new therapeutic option,
27:27being orally administered,
27:29also contributes to improving
27:31the patient's quality of life.
27:33It is a therapy that allows
27:35the person not to have to be in the hospital
27:37in order to be able to receive it
27:39in administration.
27:41This also frees the caregiver
27:43from the need to accompany
27:45the person in the hospital.
27:47An important event in the
27:49oncohematological field
27:51is also that of Tagraxofusp,
27:53a plasmocytoid endotoxin
27:55of plastics,
27:57whose effectiveness has been
27:59evidenced by a study conducted
28:01on 47 patients,
28:0332 of which were not
28:05previously treated.
28:07The results have been
28:09extremely comforting
28:11because the untreated patients
28:13have had a complete response
28:15of 72%,
28:17putting together complete
28:19and partial responses,
28:21the overall response rate
28:23we are talking about numbers of 90%.
28:25As for the patients
28:27who had already seen
28:29previous treatments,
28:3167% got an answer.
28:33Results that represent
28:35a reason for pride for Menarini,
28:37who for a few years has chosen
28:39to engage in research and development
28:41of new therapeutic solutions
28:43for blood tumors.
28:45As the Menarini Group,
28:47we are proud to have undertaken
28:49a commitment to research
28:51and development of drugs
28:53in the oncohematological field.
28:55The next steps will certainly
28:57go in this direction,
28:59trying to bring as much innovation
29:01as possible for patients affected
29:03by blood tumors.
29:07Every year in Lazio
29:09more than 3,500 new cases
29:11of lung tumors are recorded,
29:13of which almost 1,800 have a
29:15small cell form, oncogene addicted,
29:17i.e. with the forms of the disease
29:19linked to a specific genetic mutation,
29:21for some of which there are
29:23targeted oral pharmacies.
29:25If research today allows to prolong
29:27the survival of patients,
29:29clinics and institutions
29:31are working to simplify
29:33the treatment paths
29:35and allow those who need
29:37to take the treatments at home,
29:39especially in the case
29:41of oral therapies.
29:43The innovation value
29:45of the new therapies
29:47seems to be increasing,
29:49in particular for those
29:51suffering from a specific type
29:53of this neoplasia.
29:55The path in the area
29:57of lung tumors
29:59is very interesting
30:01because it allows
30:03the development
30:05of new therapies
30:07that can be used
30:09for the treatment
30:11of cancer patients.
30:13Now in the area of lung tumors
30:15we have several news,
30:17among the most important
30:19and certainly the possibility
30:21today to have available
30:23also in our country a drug
30:25aimed at a specific population
30:27of patients, which are
30:29patients with the mutation
30:31of the Kapparats gene,
30:33the drug Sotorazib,
30:35an oral drug that has
30:37shown in a clinical study
30:39to be superior to chemotherapy
30:41of treatment for this
30:43group of patients.
30:45But how is this therapy supplied
30:47and how is it dispensed?
30:49The drug is a drug that is given
30:51by oral way, the potential advantage
30:53also of this drug is the possibility
30:55that it is dispensed
30:57also by territorial asylums
30:59and this allows a more easy
31:01access to the cures
31:03by patients,
31:05both those who need to start
31:07the treatment and those patients
31:09who need to continue their therapy.
31:39The psychologist therefore becomes
31:41more and more central.
31:43The woman is disoriented because
31:45from the phase of diagnosis to the phase
31:47of subordination to treatments,
31:49often there is not even time
31:51to elaborate what is happening,
31:53so the psychologist has the role
31:55to offer a space
31:57of listening, a welcoming space
31:59that can guide her
32:01to listen to those
32:03that are new needs,
32:05to listen to those that are
32:07new discomfort, suffering,
32:09fatigue, fear.
32:11On the one hand there is
32:13the need to understand how,
32:15for example, to experience the change
32:17of your own body, of your own
32:19body image, but also
32:21how to experience, for example,
32:23the concerns of people
32:25who are around the woman,
32:27therefore more intimate relationships
32:29with children, partners, family.
32:31Many researches recognize
32:33how the role of the caregiver,
32:35the family member, is essential
32:37in favoring a good
32:39adaptation
32:41to the person's disease.
32:43Breast cancer is one of the most
32:45widespread tumors among women
32:47around the world.
32:49The diagnosis of metastatic tumor
32:51is associated with the anxiety
32:53of incurability.
32:55In fact, the advancement of
32:57treatments tells us that
32:59even the metastatic breast tumor
33:01is curable because the life expectancy
33:03is increased and therefore
33:05it is associated with a state
33:07of chronicizable disease.
33:09However, women,
33:11despite these encouraging
33:13facts,
33:15find themselves facing
33:17a very uncertain look
33:19towards the future, very
33:21frightened, very precarious,
33:23and therefore the psychological impact
33:25is very strong.
33:27Psychology, psychological interventions
33:29of a supportive,
33:31expressive nature,
33:33but also of a
33:35group psychological nature,
33:37can become those interventions
33:39that support the woman to take
33:41care of the
33:43most emotional part
33:45that has an impact
33:47on the disease.
33:49A woman who takes care
33:51of her life, who does not identify
33:53with the disease, but who integrates
33:55different aspects, different phases
33:57of her life, different areas
33:59of her life, is a woman
34:01who improves her immune responses
34:03and consequently
34:05also improves the responses
34:07of the body and treatments
34:09and consequently also the effects of the tumor.
34:11So, in this correlated and holistic
34:13perspective, taking care of
34:15psychological health is
34:17an essential factor.
34:19The new therapies available for
34:21the treatment of the metastatic breast tumor
34:23have expanded the life expectancy
34:25and therefore opened the possibility
34:27of returning to work for patients.
34:29Certainly, going back to work
34:31is a very delicate moment.
34:33The first step is certainly
34:35self-awareness
34:37and also the awareness of one's limits,
34:39as well as the legitimation
34:41of one's limits, because
34:43being subjected to
34:45life-saving treatments
34:47means having
34:49exhausted one's body,
34:51but also one's cognitive processes,
34:53as well as
34:55having exhausted
34:57the whole emotional and
34:59psychological sphere.
35:01So, recognizing fatigue,
35:03tiredness, recognizing
35:05the difficulty in concentrating,
35:07recognizing the difficulty
35:09in adapting to a working environment
35:11becomes
35:13also a care
35:15of a new adaptation process.
35:17To deepen the topic,
35:19the site is available
35:21and Tempo di Vita, a project
35:23promoted by Novartis,
35:25to support all women
35:27who face an advanced breast tumor.
35:33This was our latest news.
35:35To contact us, you can write to
35:37salute-adnchronos.com
35:39Thank you for following us
35:41and see you next time!
35:53Tempo di Vita
35:55Tempo di Vita